Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success

• Johnny Flippie Daniels ,

  * E-mail: msfocb-khayelitsha-tbdata@brussels.msf.org

  Affiliation Médecins sans Frontières, Khayelitsha, Cape Town, South Africa

  ⨯
• Mohammed Khogali,

  Affiliation Médecins sans Frontières, Luxembourg, Luxembourg

  ⨯
• Erika Mohr,

  Affiliation Médecins sans Frontières, Khayelitsha, Cape Town, South Africa

  ⨯
• Vivian Cox,

  Affiliation Médecins sans Frontières, Khayelitsha, Cape Town, South Africa

  ⨯
• Sizulu Moyo,

  Affiliations Médecins sans Frontières, Khayelitsha, Cape Town, South Africa, Human Sciences Research Council, HIV/AIDS, STIs and TB programme, Cape Town, South Africa

  ⨯
• Mary Edginton,

  Affiliations International Union against TB and Lung Disease, Paris, France, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

  ⨯
• Sven Gudmund Hinderaker,

  Affiliation University of Bergen, Bergen, Norway

  ⨯
• Graeme Meintjes,

  Affiliation Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa

  ⨯
• Jennifer Hughes,

  Affiliation Médecins sans Frontières, Khayelitsha, Cape Town, South Africa

  ⨯
• Virginia De Azevedo,

  Affiliation City of Cape Town Department of Health, Cape Town, South Africa

  ⨯
• Gilles van Cutsem,

  Affiliations Médecins sans Frontières, Khayelitsha, Cape Town, South Africa, Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa

  ⨯
• Helen Suzanne Cox

  Affiliation Division of Medical Microbiology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

  ⨯